Surgical Resection of Colorectal Liver Metastases in Patients with Expanded Indications: A Single-Center Experience with 501 Patients
| Autor: | Laura Lladó, Teresa Serrano, Carlos Valls, Joan Martí-Ragué, Emilio Ramos, Juan Fabregat, Juan Figueras, Jaume Torras |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Colorectal cancer medicine.medical_treatment Adenocarcinoma Single Center Metastasis medicine Hepatectomy Humans Survival rate Neoadjuvant therapy Aged Retrospective Studies business.industry Liver Neoplasms Gastroenterology Retrospective cohort study General Medicine Middle Aged medicine.disease Neoadjuvant Therapy Colorectal surgery Surgery Survival Rate Chemotherapy Adjuvant Female Colorectal Neoplasms business Follow-Up Studies |
| Zdroj: | Diseases of the Colon & Rectum. 50:478-488 |
| ISSN: | 0012-3706 |
| DOI: | 10.1007/s10350-006-0817-6 |
| Popis: | This study was designed to investigate survival after curative resection of colorectal liver metastases in patients with expanded indications. A total of 501 patients had 545 liver resections for metastatic colorectal cancer. There were no predefined criteria for resectability with regard to the number or size of the tumors, locoregional invasion, or extrahepatic disease, except that resection had potential to be complete and macroscopically curative. All patients who had curative hepatic resection were advised to start postoperative adjuvant chemotherapy. A total of 259 patients had expanded indications (52 percent), including 14 with liver metastases >10 cm, 194 with bilateral deposits, 140 with four or more liver metastases, and 73 with extrahepatic disease. The overall actuarial survival rates at one, three, five, and ten years were 88, 67, 45, and 36 percent, respectively, for patients with classic indications and 84, 53, 34, and 24 percent, respectively, for patients with expanded indications (P = 0.0009). In the group of expanded indications, there were more patients who received preoperative than postoperative chemotherapy: 72 (28 percent) vs. 18 (7 percent; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink